STOCK TITAN

AbCellera Biologics Inc - ABCL STOCK NEWS

Welcome to our dedicated news page for AbCellera Biologics (Ticker: ABCL), a resource for investors and traders seeking the latest updates and insights on AbCellera Biologics.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AbCellera Biologics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AbCellera Biologics's position in the market.

Rhea-AI Summary
AbCellera (ABCL) announces groundbreaking data on T-cell engager programs at AACR Annual Meeting 2024, showcasing potent tumor-cell killing and low cytokine release across multiple targets. The company aims to widen the therapeutic window, enhance potency, and broaden the accessible target space for TCEs in cancer therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.46%
Tags
none
-
Rhea-AI Summary
AbCellera (ABCL) to announce first quarter 2024 financial results on May 7, 2024, with an earnings conference call scheduled. Investors can access a live audio webcast and replay on AbCellera's Investor Relations website.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.46%
Tags
conferences earnings
-
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) executives to present at Bloom Burton Healthcare Conference. Live webcast and replay details provided.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.83%
Tags
conferences
Rhea-AI Summary
AbCellera (ABCL) partners with Biogen Inc. (BIIB) to discover antibodies for brain-targeted biotherapeutics in neuroscience. The collaboration aims to address the challenge of delivering biologics across the blood-brain barrier. AbCellera will receive upfront payment, milestone payments, and potential royalties on future product sales.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.98%
Tags
none
-
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) will present four posters at the AACR Annual Meeting 2024 showcasing data from its T-cell engager programs and platform. The company aims to develop potent tumor-cell killing T-cell engagers with low cytokine release for challenging cancer targets, including solid tumors and peptide-MHCs.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.25%
Tags
none
-
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) announces Peter Thiel's resignation from the Board of Directors for personal reasons, effective March 7, 2024. Dr. Andrew Lo to join Nominating and Corporate Governance Committee. Thiel praised AbCellera's biotech advancements. Board size to reduce from six to five directors.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
1.64%
Tags
management
Rhea-AI Summary
AbCellera (ABCL) executives to present at investor conferences, including 44th Annual TD Cowen Health Care Conference and KeyBanc Capital Markets Life Sciences & MedTech Investor Forum.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.41%
Tags
conferences
-
Rhea-AI Summary
AbCellera (ABCL) reported total revenue of $38 million for FY 2023, with a net loss of $146.4 million. The company reached 87 partner-initiated program starts, advanced 13 molecules into the clinic, and had $1 billion in available liquidity.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-9.42%
Tags
none
-
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) is set to announce its full year 2023 financial results on February 20, 2024, and will hold an earnings conference call on the same day. The live audio webcast can be accessed through AbCellera’s Investor Relations website, with a replay available following the conference call.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-0.94%
Tags
conferences earnings
Rhea-AI Summary
AbCellera (Nasdaq: ABCL) executives to present at 42nd Annual J.P. Morgan Healthcare Conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
4.79%
Tags
conferences
AbCellera Biologics Inc

Nasdaq:ABCL

ABCL Rankings

ABCL Stock Data

1.19B
191.76M
28.09%
43.66%
8.06%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
CA
Vancouver

About ABCL

abcellera is a canadian biotechnology company focused on accelerating the discovery of monoclonal antibody (mabs) therapeutics. antibodies are molecules that are naturally produced by the immune system of humans or animals to fight off infection and disease. the unique property of antibodies is that they can specifically recognize and target diseased cells or pathogens, making them precise and highly effective drugs with low side effects for the treatment of cancer, autoimmune disorders and infections. the immune system is capable of making billions to trillions of unique antibodies, each produced by a single immune cell. of these, only a select few are suitable for therapeutic applications. finding these rare antibodies presents a major roadblock in the development of new therapeutics. abcellera addresses this bottleneck by using microfluidic technology for the rapid and high-throughput analysis of antibodies directly from single cells. abcellera is a spinoff from dr. carl hansen’